Leinco Technologies is a leader in the development and manufacturing of antibodies and recombinant proteins for early discovery research and diagnostics. In response to the ongoing worldwide pandemic, Leinco Technologies offers an extensive line of SARS-CoV-2 antibodies and antigens at the highest functional purity levels you have come to know and trust. Leinco’s COVID-19 Neutralization MICRO-ELISA and COVID-19 IgG Serology Assay has completed Section IV.D notification process under FDA’s “Policy for Coronavirus Disease – 2019 Test During the Public Health Emergency (Revised)“ and has not been reviewed by FDA.
Clone
Format
Reactive Species
Specificity
Host Species
Product Type
Reported Applications
Can't find what you're looking for?
10 per page
Sort by
Toggle Details
Showing 51 – 60 of 82 results Showing all 82 results Showing the single result No results found
- -
- -
Name | Applications ? | Prod No. | Clone | Pkg. Size / Quantity |
|---|---|---|---|---|
Alt Names: COV2-2146, SARS-CoV2 Spike NTD, COVID-19, 2019-nCoV, Severe acute respiratory syndrome coronavirus 2, SARS-CoV2 Reactivity: SARS-CoV-2 ⋅ Virus Immunogen: Sequenced from human survivors of COVID-19 (SARS-CoV-2) | ELISA , IHC | LT2005 | 2146 | |
Alt Names: COV2-2146, SARS-CoV2 Spike NTD, COVID-19, 2019-nCoV, Severe acute respiratory syndrome coronavirus 2, SARS-CoV2 Reactivity: SARS-CoV-2 ⋅ Virus Immunogen: Sequenced from human survivors of COVID-19 (SARS-CoV-2) | ELISA , IHC | LT2010 | 2146 | |
Alt Names: COV2-2215, SARS-CoV2 Spike NTD, COVID-19, 2019-nCoV, Severe acute respiratory syndrome coronavirus 2, SARS-CoV2 Reactivity: SARS-CoV-2 ⋅ Virus Immunogen: Sequenced from human survivors of COVID-19 (SARS-CoV-2) | ELISA | LT6000 | 2215 | |
Alt Names: SARS-CoV-2 (COVID-19, 2019-nCoV) Spike Antibody: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Surface Glycoprotein, Spike protein Reactivity: Virus Immunogen: Anti-SARS-CoV-2 (COVID-19, 2019-nCoV) Spike antibody was raised against a peptide corresponding to 20 amino acids near the carboxy terminus of SARS-CoV-2 (COVID-19, 2019-nCoV) Spike glycoprotein. The immunogen is located within the last 50 amino acids of SARS-CoV-2 (COVID-19, 2019-nCoV) Spike protein. | ELISA , IF , WB | S540 | ||
Alt Names: SARS-CoV-2 Spike RBD Antibody, Receptor-Binding Domain, Spike | ELISA | S125 | ||
Alt Names: COV2-2143, SARS-CoV-2 Spike Antibody Reactivity: SARS-CoV-2 ⋅ Virus Immunogen: Sequenced from human survivors of COVID-19 (SARS-CoV-2) | ELISA | LT3500 | 2143 | |
Alt Names: COV2-2165, SARS-CoV-2 Spike RBD Antibody, Receptor Binding Domain Monoclonal Antibody Reactivity: SARS-CoV-2 ⋅ Virus Immunogen: Sequenced from human survivors of COVID-19 (SARS-CoV-2) | ELISA , IHC | LT1905 | 2165 | |
Alt Names: COV2-2165, SARS-CoV-2 Spike RBD Antibody, Receptor Binding Domain Monoclonal Antibody Reactivity: SARS-CoV-2 ⋅ Virus Immunogen: Sequenced from human survivors of COVID-19 (SARS-CoV-2) | ELISA , IHC | LT1910 | 2165 | |
Alt Names: COV2-2196, SARS-CoV-2 Spike RBD Antibody, Receptor Binding Domain Monoclonal Antibody Reactivity: SARS-CoV-2 ⋅ Virus Immunogen: Sequenced from human survivors of COVID-19 (SARS-CoV-2) | ELISA | LT8005 | 2196 | |
Alt Names: COV2-2196, SARS-CoV-2 Spike RBD Antibody, Receptor Binding Domain Monoclonal Antibody Reactivity: SARS-CoV-2 ⋅ Virus Immunogen: Sequenced from human survivors of COVID-19 (SARS-CoV-2) | ELISA | LT8010 | 2196 |
